The global RAS-acting Agents Market was valued at USD 9.7 billion in 2022 and is projected to surpass USD 13.4 billion by the end of 2031. The market is expected to expand at a CAGR of 4.2% from 2023 to 2031, driven by the rising prevalence of cancer and chronic diseases, increasing demand for targeted therapies, and continuous advancements in precision medicine and biotechnology research.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85539

Market Overview

The renin-angiotensin system (RAS) is a complex hormonal system that helps regulate blood pressure and fluid balance in the body. RAS-acting agents/drugs target different components of this system and are used to treat various cardiovascular and renal disorders. The action of ACE enzymes, which convert angiotensin I to angiotensin II, is blocked by angiotensin-converting enzyme (ACE) inhibitors. Angiotensin II is a potent vasoconstrictor that can raise blood pressure. ACE inhibitors, such as lisinopril, enalapril, and captopril, lower blood pressure by reducing the production of angiotensin II.

RAS-acting agents significantly impact cardiovascular and renal health and are used to manage various conditions related to high blood pressure and heart failure. However, these could also cause side effects such as hypotension, cough, and hyperkalemia. Hence, they should be used under the guidance of a healthcare professional.

Analysts’ Viewpoint

Continuous research & development, increase in prevalence of cardiovascular diseases (CVDs), and development of new combination therapies and precision medicine approaches are driving the global RAS-acting agents market. Increase in investment by pharmaceutical companies in research & development, particularly in the area of CVDs, are expected to propel market expansion.

Combination therapies that target multiple aspects of the renin-angiotensin system (RAS) are gaining popularity, as these can be more effective than single-agent therapies. Manufacturers primarily focus on the development of new combination therapies in order to increase market share and presence.

Analysis of Key Players

The market is a mix of high-volume generic manufacturers and R&D-heavy innovators focusing on novel molecular mechanisms.

Leading companies operating in the global antihyperlipidemic drugs market include:

• Novartis AG
• Pfizer, Inc.
• AstraZeneca plc
• Merck & Co., Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim GmbH
• Johnson & Johnson
• Other Prominent Players

Strategic moves in 2026 show a focus on Fixed-Dose Combinations (FDCs), where companies are combining statins with newer agents like bempedoic acid to simplify treatment regimens.

Recent Developments (2025–2026)

• In November 2021, Boehringer Ingelheim announced the launch of a new fixed-dose combination product containing telmisartan and amlodipine besylate for the treatment of hypertension. The product, called Twynsta Duo, is now available in the U.S.
• In October 2021, AstraZeneca and Amgen announced the results of phase 3 clinical trial of their RAS-acting agent, tezepelumab, in patients with severe asthma. The trial met its primary endpoint of reducing asthma exacerbations. The companies plan to seek regulatory approval for the drug.
• In August 2021, Pfizer announced that its RAS-acting agent, tafamidis, received approval from the European Commission for the treatment of transthyretin amyloid cardiomyopathy, a rare and life-threatening condition that affects the heart.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=85539

Key Developments & Trends

• RNAi Revolution: Expansion of small interfering RNA (siRNA) therapies that offer “vaccine-like” dosing schedules (once or twice a year).
• Statin-Intolerance Niche: Rapid growth of Bempedoic Acid as the preferred alternative for the ~10% of patients who cannot tolerate statins.
• Combination Proliferation: Rising use of ezetimibe/statin combinations to achieve aggressive LDL targets (below 55 mg/dL) for high-risk patients.
• Digital Health Integration: Use of mobile apps and wearables to monitor lipid levels and improve adherence to lifelong medication.
• Bile Acid Sequestrant Resurgence: Renewed interest in sequestrants as “add-on” therapies for patients with complex mixed dyslipidemia.

Challenges

• High Cost of Biologics: Specialty drugs like PCSK9 inhibitors remain priced at a premium, limiting adoption in emerging economies.
• Generic Erosion: Massive availability of low-cost statin generics limits the revenue potential for new branded oral entrants.
• Patient Non-Adherence: Despite new therapies, nearly 30% of patients stop taking lipid-lowering medication within the first year.
• Regulatory Hurdles: Stringent requirements for proving long-term “cardiovascular outcome” (CVOT) data for new drug classes.

Opportunities

• Emerging Markets (APAC): High growth potential in India and Southeast Asia due to changing diets and improved screening.
• Rare Disease Focus: Development of “Orphan Drugs” for conditions like Homozygous Familial Hypercholesterolemia (HoFH).
• Telehealth Growth: Expansion of online/e-pharmacies for the convenient delivery of maintenance medications.
• Point-of-Care Testing (POCT): Demand for rapid lipid panel tests that allow for immediate prescription adjustments during a single clinic visit.

Market Segmentation

➤ By Drug Class

• Statins (Market Leader ~39.9% share)
• PCSK9 Inhibitors (Fastest Growing ~8.4% CAGR)
• Cholesterol Absorption Inhibitors (e.g., Ezetimibe)
• Bile Acid Sequestrants
• Fibric Acid Derivatives (Fibrates)
• Combination Therapies

➤ By Route of Administration

• Oral (Dominant ~74% share)
• Injectable/Parenteral (Rapidly expanding via biologics)

➤ By Indication

• Hypercholesterolemia (~41.1% share)
• Hypertriglyceridemia
• Mixed Dyslipidemia
• Familial Hypercholesterolemia

➤ By Distribution Channel

• Hospital Pharmacies (Leading for acute/specialty starts)
• Retail Pharmacies (Core for chronic refills)
• Online/E-Pharmacies

Conclusion

The antihyperlipidemic drugs market in 2026 is shifting from mass-market statins to precision biologics. Through 2035, the market will be defined by dosing convenience and cost-effectiveness. As the industry embraces “ultra-long-acting” injectables and addresses the high-risk “statin-intolerant” population, the manufacturers that balance clinical efficacy with simplified patient journeys will lead the cardiovascular landscape.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=85539&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com